EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study

Eva Cervilla-Muñoz, Pablo Demelo-Rodríguez iD, Rubén Alonso-Beato iD, Miriam Juárez-Fernández, Iago Sousa-Casasnovas, Lucía Ordieres-Ortega iD, Marina López-Rubio iD, Luis-Antonio Alvarez-Sala Walther, Francisco Galeano-Valle

Journal of Clinical Medicine · 12.04.2026 · 15 (8) · 2932

DOI: 10.3390/jcm15082932 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.04.2026. Verfasst von Eva Cervilla-Muñoz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Venous Thromboembolism Unit, Internal Medicine Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of systemic fibrinolysis in patients with intermediate-risk pulmonary embolism (PE) remains controversial because of the uncertain balance between potential benefits and bleeding risk. This study evaluated the association between systemic fibrinolysis and clinical outcomes in a real-world cohort of patients with symptomatic intermediate-risk PE.

Methods

This prospective observational study included consecutive patients with symptomatic intermediate-risk PE from 2009 to 2019 at a tertiary hospital. Patients receiving systemic fibrinolysis were compared with those treated with anticoagulation alone. The primary outcome was 30-day all-cause mortality. Secondary outcomes included major bleeding, and recurrent venous thromboembolism. Multivariable Cox proportional hazards regression models were used to adjust for potential confounders.

Results

A total of 560 patients with symptomatic intermediate-risk PE were included, of whom 54 (9.6%) received systemic fibrinolysis. Patients receiving fibrinolysis were younger than those treated with anticoagulation alone (median age 58 vs. 73 years; p < 0.001). Thirty-day mortality occurred in 1.8% and 3.3% of patients, respectively (p = 1). After adjustment, fibrinolysis was not associated with reduced 30-day mortality (aHR 1.5; 95% CI 0.1–17.9), nor with a significant increase in 30-day major bleeding (aHR 2.6; 95% CI 0.8–8.3). Intracranial hemorrhage and VTE recurrences were rare.

Conclusions

In this real-world cohort, systemic fibrinolysis was not associated with improved survival compared with anticoagulation alone, consistent with current guideline recommendations against routine fibrinolysis in intermediate-risk PE.

Schlagwörter

Stichwörter der Autor:innen

anticoagulationmortalitypulmonary embolismsystemic fibrinolysis

Autor:innen und Institutionen

  • Venous Thromboembolism Unit, Internal Medicine Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
  • Department of Cardiology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Pablo Demelo-Rodríguez, Rubén Alonso-Beato, Lucía Ordieres-Ortega, Marina López-Rubio

Zitieren

APA

Cervilla-Muñoz, E., Demelo-Rodríguez, P., Alonso-Beato, R., Juárez-Fernández, M., Sousa-Casasnovas, I., Ordieres-Ortega, L., López-Rubio, M., Alvarez-Sala Walther, L. A., & Galeano-Valle, F. (2026). Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study. Journal of Clinical Medicine, 15(8), 2932. https://doi.org/10.3390/jcm15082932

Vancouver

Cervilla-Muñoz E, Demelo-Rodríguez P, Alonso-Beato R, Juárez-Fernández M, Sousa-Casasnovas I, Ordieres-Ortega L, et al. Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study. Journal of Clinical Medicine. 2026;15(8):2932. doi:10.3390/jcm15082932

BibTeX
@article{CervillaMuoz2026,
  author = {Cervilla-Muñoz, Eva and Demelo-Rodríguez, Pablo and Alonso-Beato, Rubén and Juárez-Fernández, Miriam and Sousa-Casasnovas, Iago and Ordieres-Ortega, Lucía and López-Rubio, Marina and Alvarez-Sala Walther, Luis-Antonio and Galeano-Valle, Francisco},
  title = {Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {2932},
  doi = {10.3390/jcm15082932}
}
Kostenlos starten →